PROJECT STAGE
Lead optimisation
Hit to lead
Screening
Assay Development
Therapeutic area
  • Neuropathic Pain

Project Aim

To develop an agonist of Galanin Receptor 2 (GalR2) for the treatment of pain

Advantage

Potential to address current unmet need in chronic pain with an improved side-effect profile to current therapies

Target Class

G-Protein Coupled Receptor (GPCR)

Modality

Biotherapeutic agent

Current Status

Discovery with in-vivo proof of efficacy

Intellectual Property

Opportunity to create a protective IPR portfolio

Offering

Licence or collaboration for pre-clinical / clinical development

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities